COMBINATION THERAPY WITH CGRP ANTAGONISTS
Disclosed are methods for treating headache, migraine and related symptoms by administering a long acting calcitonin gene related peptide (CGRP) antagonist and a short acting CGRP antagonist. Specifically, the disclosure provides a method for treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first calcitonin gene related peptide antagonist (CGRP antagonist) and (b) a second CGRP-antagonist, wherein the first CGRP antagonist is an antibody, and the second CGRP antagonist has a plasma half-life in humans of at most about 60 hours..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 03. Aug. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
JAKATE ABHIJEET [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-08-03, Last update posted on www.tib.eu: 2023-09-27, Last updated: 2023-09-29 |
---|
Patentnummer: |
EP4034156 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA002109697 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | EPA002109697 | ||
003 | DE-627 | ||
005 | 20240327214701.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240327s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA002109697 | ||
035 | |a (EPA)EP4034156 | ||
035 | |a (EPA)75166845 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a JAKATE ABHIJEET |e verfasserin |4 aut | |
245 | 1 | 0 | |a COMBINATION THERAPY WITH CGRP ANTAGONISTS |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-08-03, Last update posted on www.tib.eu: 2023-09-27, Last updated: 2023-09-29 | ||
520 | |a Disclosed are methods for treating headache, migraine and related symptoms by administering a long acting calcitonin gene related peptide (CGRP) antagonist and a short acting CGRP antagonist. Specifically, the disclosure provides a method for treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first calcitonin gene related peptide antagonist (CGRP antagonist) and (b) a second CGRP-antagonist, wherein the first CGRP antagonist is an antibody, and the second CGRP antagonist has a plasma half-life in humans of at most about 60 hours. | ||
650 | 4 | |a che | |
650 | 4 | |a C12P: Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a bio | |
650 | 4 | |a 615 | |
700 | 0 | |a PERICLOU ANTONIA |4 aut | |
700 | 0 | |a BOINPALLY RAMESH |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 03. Aug. |
773 | 1 | 8 | |g year:2022 |g day:03 |g month:08 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75166845/publication/EP4034156A1?q=EP4034156 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2022 |b 03 |c 08 |